February 2013

TreatmentTrends®: Crohn's Disease (US) 2013


TreatmentTrends® Crohn’s Disease (CD) is a report that covers the use of biologics for the treatment of CD. The report focuses on current and future use of CD treatments, patient market share, perceived strengths and weaknesses of the key brands, barriers to broader usage, and sales force performance.
TreatmentTrends® are syndicated report series that provide longitudinal information on market dynamics. They provide insight into practice patterns, attitudes and perceptions, and current and projected use of various products. They evaluate perceived product advantages and disadvantages, as well as sales and messaging efforts of key market players.

Questions Answered in This Report:

  *   Determine the typical patient load, diagnosis and prevalence of biologic treatment among gastroenterologists for CD

  *   Understand how and why biologic use is expected to shift among gastroenterologists in the next six months for CD

  *   Compare the biologics in terms of CD market share (current and future) and highlight the leading obstacles to brand growth

  *   Understand the unmet needs in the CD biologics market

  *   Understand the attributes that gastroenterologists feel are most important with the various biologics used to treat patients with Crohn’s Disease

  *   Evaluate awareness of products in development and understand which product attributes will be most desirable in future biologic agents


Sample Frame & Methodology:

- 100 gastroenterologists will complete a 45- minute online quantitative survey

To qualify for participation, rheumatologists must meet the following criteria:

- Board Certified in gastroenterology

- In practice between 2 and 30 years

- Minimum of 30 CD patients under their personal management

- Minimum of 10 CD patients being treated with biologic agents


- Powerpoint decks to be published

- Complete set of frequency tables, summary statistics, and cross tabulations

- Up to three proprietary questions answered per client in each wave

Product Coverage:

Approved: Cimzia, Humira, Remicade, and Tysabri

Off Label: Simponi

In development: Vedolizumab (MLB-0002), Stelara (Ustekinumab), Vercirnon (formerly GSK-1605786, Traficit-EN or CCX-282B), and Prochymal (OTI-010)

Related 2013 Reports:

- TreatmentTrends®: Crohn's Disease (EU)

- TreatmentTrends®: Ulcerative Colitis (US)

- TreatmentTrends®: Ulcerative Colitis (EU)

Related 2012 Reports:

- TreatmentTrends®: Crohn's Disease (US)

- PatientTrends®: Crohn's Disease (US)

- ChartTrends®: Crohn's Disease (US)

- TreatmentTrends®: Ulcerative Colitis (US)

- PatientTrends®: Ulcerative Colitis (US)

Search Published Reports

Decision Resources Group brands include: